Sun Pharma
-
Sun Pharma receives Organon shareholder approval for US$11.75B acquisition
Sun Pharma disclosed the development in an exchange filing, confirming that Organon stockholders had voted in favour of the proposals required to advance the proposed merger transaction.
-
Sun Pharma expands domestic footprint with US$28.7M Innovcare Lifesciences acquisition
Mumbai-based Innovcare Lifesciences operates across the Indian market and focuses on marketing, distributing, and selling pharmaceutical products, nutraceuticals, and cosmeceuticals.
-
Sun Pharma to acquire Organon for US$11.75B to dominate global women’s health
The acquisition is expected to strengthen Sun Pharma’s global footprint while broadening its presence in women’s health, biosimilars, and established medicines.
-
Sun Pharma to invest USD590M in new Assam manufacturing plant
Once fully operational, the manufacturing plant is expected to create direct employment opportunities for more than 500 people.
-
Sun Pharma brings Cosibelimab to U.S. for advanced skin cancer
The U.S. Food and Drug Administration (FDA) recently approves an updated label for UNLOXCYT based on long-term follow-up data from the pivotal CK-301-101 clinical trial.